vs
Maison Solutions Inc.（MSS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Maison Solutions Inc.的1.1倍（$30.3M vs $27.6M），Maison Solutions Inc.净利率更高（-18.0% vs -221.3%，领先203.4%），REGENXBIO Inc.同比增速更快（43.0% vs -10.9%），过去两年Maison Solutions Inc.的营收复合增速更高（42.5% vs 39.4%）
Maison Solutions Inc.是一家专注于家居零售的企业，主要运营市场位于中国粤港澳大湾区，面向大众消费者提供高性价比的时尚家具、家居装饰用品及日常家用百货，同时布局线下实体门店与线上电商销售渠道。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MSS vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.1倍
$27.6M
营收增速更快
RGNX
高出54.0%
-10.9%
净利率更高
MSS
高出203.4%
-221.3%
两年增速更快
MSS
近两年复合增速
39.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $27.6M | $30.3M |
| 净利润 | $-5.0M | $-67.1M |
| 毛利率 | 23.4% | — |
| 营业利润率 | -4.9% | -190.0% |
| 净利率 | -18.0% | -221.3% |
| 营收同比 | -10.9% | 43.0% |
| 净利润同比 | -1840.5% | -31.2% |
| 每股收益（稀释后） | $-0.23 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MSSRGNX
| Q4 25 | $27.6M | $30.3M | ||
| Q3 25 | $27.2M | $29.7M | ||
| Q2 25 | $34.4M | $21.4M | ||
| Q1 25 | $32.3M | $89.0M | ||
| Q4 24 | $29.4M | $21.2M | ||
| Q3 24 | $28.2M | $24.2M | ||
| Q2 24 | $16.9M | $22.3M | ||
| Q1 24 | $13.6M | $15.6M |
净利润MSSRGNX
| Q4 25 | $-5.0M | $-67.1M | ||
| Q3 25 | $-1.5M | $-61.9M | ||
| Q2 25 | $-287.4K | $-70.9M | ||
| Q1 25 | $1.0M | $6.1M | ||
| Q4 24 | $-256.0K | $-51.2M | ||
| Q3 24 | $700.9K | $-59.6M | ||
| Q2 24 | $-2.8M | $-53.0M | ||
| Q1 24 | $-549.0K | $-63.3M |
毛利率MSSRGNX
| Q4 25 | 23.4% | — | ||
| Q3 25 | 24.1% | — | ||
| Q2 25 | 9.5% | — | ||
| Q1 25 | 21.8% | — | ||
| Q4 24 | 26.9% | 70.2% | ||
| Q3 24 | 28.9% | 48.8% | ||
| Q2 24 | 13.0% | 52.5% | ||
| Q1 24 | 23.4% | 72.6% |
营业利润率MSSRGNX
| Q4 25 | -4.9% | -190.0% | ||
| Q3 25 | 0.7% | -176.3% | ||
| Q2 25 | -15.9% | -296.3% | ||
| Q1 25 | 3.7% | 13.6% | ||
| Q4 24 | 3.2% | -242.1% | ||
| Q3 24 | 7.3% | -256.6% | ||
| Q2 24 | -14.4% | -251.3% | ||
| Q1 24 | -2.3% | -408.8% |
净利率MSSRGNX
| Q4 25 | -18.0% | -221.3% | ||
| Q3 25 | -5.7% | -208.3% | ||
| Q2 25 | -0.8% | -331.8% | ||
| Q1 25 | 3.1% | 6.8% | ||
| Q4 24 | -0.9% | -241.3% | ||
| Q3 24 | 2.5% | -246.3% | ||
| Q2 24 | -16.4% | -237.7% | ||
| Q1 24 | -4.0% | -405.4% |
每股收益（稀释后）MSSRGNX
| Q4 25 | $-0.23 | $-1.30 | ||
| Q3 25 | $-0.08 | $-1.20 | ||
| Q2 25 | $-0.02 | $-1.38 | ||
| Q1 25 | $0.06 | $0.12 | ||
| Q4 24 | $-0.01 | $-0.99 | ||
| Q3 24 | $0.04 | $-1.17 | ||
| Q2 24 | $-0.16 | $-1.05 | ||
| Q1 24 | $-0.03 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $2.6M | — |
| 股东权益账面价值 | $11.6M | $102.7M |
| 总资产 | $75.4M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.22× | — |
8季度趋势，按日历期对齐
现金及短期投资MSSRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | $1.1M | $274.2M | ||
| Q2 25 | $775.4K | $323.3M | ||
| Q1 25 | $445.4K | $267.9M | ||
| Q4 24 | $355.7K | $234.7M | ||
| Q3 24 | $588.9K | $255.5M | ||
| Q2 24 | $2.1M | $290.4M | ||
| Q1 24 | $9.4M | $338.7M |
总债务MSSRGNX
| Q4 25 | $2.6M | — | ||
| Q3 25 | $2.6M | — | ||
| Q2 25 | $2.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.5M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $2.6M | — |
股东权益MSSRGNX
| Q4 25 | $11.6M | $102.7M | ||
| Q3 25 | $10.1M | $161.5M | ||
| Q2 25 | $11.7M | $213.7M | ||
| Q1 25 | $12.0M | $274.2M | ||
| Q4 24 | $10.9M | $259.7M | ||
| Q3 24 | $11.2M | $301.4M | ||
| Q2 24 | $10.5M | $348.3M | ||
| Q1 24 | $13.3M | $390.7M |
总资产MSSRGNX
| Q4 25 | $75.4M | $453.0M | ||
| Q3 25 | $73.3M | $525.2M | ||
| Q2 25 | $77.4M | $581.0M | ||
| Q1 25 | $82.7M | $490.9M | ||
| Q4 24 | $82.7M | $466.0M | ||
| Q3 24 | $82.1M | $519.1M | ||
| Q2 24 | $82.4M | $569.4M | ||
| Q1 24 | $44.2M | $629.2M |
负债/权益比MSSRGNX
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | 0.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MSSRGNX
| Q4 25 | $-1.7M | $-52.3M | ||
| Q3 25 | $1.1M | $-56.0M | ||
| Q2 25 | $-1.6M | $-49.3M | ||
| Q1 25 | $1.7M | $33.6M | ||
| Q4 24 | $1.1M | $-31.6M | ||
| Q3 24 | $3.6M | $-40.5M | ||
| Q2 24 | $-2.6M | $-45.5M | ||
| Q1 24 | $-1.4M | $-55.5M |
自由现金流MSSRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率MSSRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度MSSRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率MSSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.66× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.12× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
